Abstract:Purpose: A dearth in pediatric drug development often leaves pediatricians with no alternative but to prescribe unlicensed or off-label drugs with a resultant increased risk of adverse events. We present the current status of pediatric drug development and, based on our data analysis, clarify the problems in this area. Further action is proposed to improve the drug development that has pediatric therapeutic orphan status. Methods: We analyzed all Phase II/III and Phase III trials in ClinicalTrials.gov that only included pediatric participants (<18 years old) between 2006 and 2014. Performance index, an indicator of pediatric drug development, was calculated by dividing the annual number of pediatric clinical trials by million pediatric populations acquired from Census.gov. Effects of the 2 Japanese premiums introduced in 2010, for the enhancement of pediatric drug development, were analyzed by comparing mean performance index prepremiums (2006-2009) and postpremiums (2010-2014) among Japan, the European Union, and the United States. The European Union Clinical Trials Register and published reports from the European Medicines Agency were also surveyed to investigate the Paediatric Committee effect on pediatric clinical trials in the European Union. Findings: Mean difference of the performance index in prepremiums and postpremiums between Japan and the European Union were 0.296 (P < 0.001) and 0.066 (P = 0.498), respectively. Those between Japan and the United States were 0.560 (P < 0.001) and 0.281 (P = 0.002), indicating that pediatric drug development in Japan was more active after the introduction of these premiums, even reaching the level of the European Union. The Pediatric Regulation and the Paediatric Committee promoted pediatric drug development in the European Union. The registered number of clinical trials that includes at least 1 participants <18 years old in the European Union Clinical Trials Register increased by 247 trials (from 672) in the 1000 days after regulation. The ratio of pediatric clinical trials with an approved Paediatric Investigation Plan increased to >15% after 2008. Implications: Recruitment and ethical obstacles make conducting pediatric clinical trials challenging. An improved operational framework for conducting clinical trials should mirror the ever-improving regulatory framework that incentivizes investment in pediatric clinical trials. Technological approaches, enhancements in electronic medical record systems, and community approaches that actively incorporate input from physicians, researchers, and patients could offer a sustainable solution to recruitment of pediatric study participants. The key therefore is to improve pediatric pharmacotherapy collaboration among industry, government, academia, and community. Expanding the regulatory steps taken in the European Union, United States, and Japan and using innovative clinical trial tools can move pediatric pharmacotherapy out of its current therapeutic orphan state.

Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development

The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases

European priority review vouchers for neglected disease product development

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience

Impact of Priority Review Voucher Eligibility on Research and Development of Medical Countermeasures

Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Novel Design and Analysis for Rare Disease Drug Development

Challenges of developing and conducting clinical trials in rare disorders

Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

Clinical development and marketing application review times for novel orphan-designated drugs

FDA's Expedite Development Program for the Therapies for Serious Conditions

A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases

A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs

Expediting treatments in the 21st century: orphan drugs and accelerated approvals

[Current Status and Issues in Drug Development for Rare Cancers]

The next generation of rare disease drug policy: ensuring both innovation and affordability

Pharmaceutical policy and innovation for rare diseases: A narrative review